Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Here's Why

Key Points

• AAPG shares fell at Monday’s open, dropping from a previous close of $19.00 to $18.30 and last trading at $18.15 on volume of 1,128 shares.
• Analysts remain broadly bullish: the stock has an average “Buy” rating, including two Strong Buy ratings, and a consensus price target of $46.43. Recent targets range from $40 to $48.
• Institutional interest has increased, with UBS boosting its position by 149.4% and HSBC Holdings and Citadel Advisors initiating new stakes. Ascentage is a clinical-stage biotech developing small-molecule cancer therapies targeting cell-death pathways.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $19.00, but opened at $18.30. Ascentage Pharma Group International shares last traded at $18.15, with a volume of 1,128 shares.

Analyst Ratings Changes

A number of analysts have weighed in on AAPG shares. BTIG Research reiterated a "buy" rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a "buy" rating and a $40.00 target price on the stock. Raymond James Financial reiterated a "buy" rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial initiated coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a "buy" rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $46.43.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average price of $18.15 and a 200 day moving average price of $21.43.

Hedge Funds Weigh In On Ascentage Pharma Group International

Institutional investors have recently modified their holdings of the business. UBS Group AG boosted its position in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company's stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Finally, Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source